🔎 Trials Near Me

Domov › Trojnásobne negatívny karcinóm prsníka › Pennsylvania

Klinické štúdie Trojnásobne negatívny karcinóm prsníka v štáte Pennsylvania

23 štúdií pre Trojnásobne negatívny karcinóm prsníka hľadá účastníkov v zariadeniach v štáte Pennsylvania.

Mestá v štáte Pennsylvania

Oficiálny text štúdie (anglicky)

The Evaluation of PC14586 in Patients With Advanced Solid Tumors Harboring a TP53 Y220C Mutation (PYNNACLE)

  • Abramson Cancer Center of the University of Pennsylvania, Philadelphia
  • University of Pittsburgh Medical Center, Pittsburgh
  • WellSpan York Cancer Center, York
Prebieha náborFáza 1/2
Vek 12 a viac · Všetky pohlavia · Aktualizované 2. 10. 2026 · NCT04585750

A Study With NKT3964 for Adults With Advanced/Metastatic Solid Tumors

  • Sidney Kimmell Cancer Center - Jefferson Health, Philadelphia
Prebieha náborFáza 1
Vek 19 a viac · Všetky pohlavia · Aktualizované 1. 10. 2026 · NCT06586957

Study of AVZO-021 in Patients With Advanced Solid Tumors

  • Avenzo Therapeutics Recruiting Site, Philadelphia
Prebieha náborFáza 1/2
Vek 18 a viac · Všetky pohlavia · Aktualizované 28. 9. 2026 · NCT05867251

Multicenter Trial for Eliminating Breast Cancer Surgery or Radiotherapy in Exceptional Responders to Neoadjuvant Systemic Therapy

  • University of Pittsburgh Cancer Institute (UPCI), Pittsburgh
Prebieha nábor
Vek 30 a viac · Ženy · Aktualizované 25. 9. 2026 · NCT02945579

Sacituzumab Tirumotecan (MK-2870) Plus Pembrolizumab Versus TPC in TNBC Who Did Not Achieve pCR (MK-2870-012)

  • Sidney Kimmel Cancer Center at Jefferson ( Site 0049), Philadelphia
  • Cancer Care Associates Of York ( Site 9517), York
Prebieha náborFáza 3
Vek 18 a viac · Všetky pohlavia · Aktualizované 25. 9. 2026 · NCT06393374

Evolutionary Clinical Trial for Novel Biomarker-Driven Therapies

  • University of Pennsylvania/Abramson Cancer Center, Philadelphia
Prebieha náborFáza 2
Vek 18 a viac · Všetky pohlavia · Aktualizované 18. 9. 2026 · NCT07340541

A Study of [225Ac]Ac-AKY-1189 in Patients With Solid Tumors

  • UPMC, Pittsburgh
Prebieha náborFáza 1
Vek 18 a viac · Všetky pohlavia · Aktualizované 17. 9. 2026 · NCT07020117

Testing the Addition of an Individualized Vaccine to Durvalumab and Tremelimumab and Chemotherapy in Patients With Metastatic Triple Negative Breast Cancer

  • UPMC Hillman Cancer Center, Pittsburgh
Prebieha náborFáza 2
Vek 18 a viac · Všetky pohlavia · Aktualizované 9. 9. 2026 · NCT03606967

Study of Sacituzumab Govitecan-hziy and Pembrolizumab Versus Treatment of Physician's Choice in Patients With Triple Negative Breast Cancer Who Have Residual Invasive Disease After Surgery and Neoadjuvant Therapy (ASCENT-05/AFT-65 OptimICE-RD/GBG 119/NSABP B-63)

  • Lancaster General Health, Lancaster
  • University of Pennsylvania Abramson Cancer Center, Philadelphia
  • UPMC Magee-Womens Hospital, Pittsburgh
  • a 3 ďalších
Prebieha náborFáza 3
Vek 18 a viac · Všetky pohlavia · Aktualizované 9. 9. 2026 · NCT05633654

A Study With NKT5097 for Adults With Advanced/Metastatic Solid Tumors

  • UPMC Hillman Cancer Center, Pittsburgh
Prebieha náborFáza 1
Vek 18 a viac · Všetky pohlavia · Aktualizované 28. 8. 2026 · NCT07029399

A Study to Investigate Safety of AZD6750 in Adult Participants With Select Advanced or Metastatic Solid Tumors

  • Research Site, Pittsburgh
Prebieha náborFáza 1/2
Vek 18 a viac · Všetky pohlavia · Aktualizované 19. 8. 2026 · NCT07115043

A Phase 1 Study of NRM-823 in Participants With Locally Advanced or Metastatic Refractory Solid Tumors

  • Normunity Investigational Site, Philadelphia
  • Normunity Investigational Site, Philadelphia
Prebieha náborFáza 1
Vek 18 a viac · Všetky pohlavia · Aktualizované 18. 8. 2026 · NCT07182149

A Study of Izalontamab Brengitecan Versus Chemotherapy in Participants With Previously Untreated, Locally Advanced, Recurrent Inoperable, or Metastatic Triple-negative Breast Cancer Ineligible for Anti-PD(L)1 Drugs (IZABRIGHT-Breast01)

  • Lehigh Valley Health Network, Allentown
  • Abramson Cancer Center of The University of Pennsylvania, Philadelphia
  • Local Institution - 0360, Pittsburgh
Prebieha náborFáza 2/3
Vek 18 a viac · Všetky pohlavia · Aktualizované 10. 8. 2026 · NCT06926868

Rinatabart Sesutecan (Rina-S, PRO1184, GEN1184) for Advanced Solid Tumors (GCT1184-01/ PRO1184-001)

  • USOR Alliance Cancer Specialist, Doylestown
  • Allegheny Health Network, Pittsburgh
Prebieha náborFáza 1/2
Vek 18 a viac · Všetky pohlavia · Aktualizované 4. 8. 2026 · NCT05579366

I-SPY TRIAL: Neoadjuvant and Personalized Adaptive Novel Agents to Treat Breast Cancer

  • University of Pennsylvania (U Penn), Philadelphia
Prebieha náborFáza 2
Vek 18 a viac · Všetky pohlavia · Aktualizované 6. 5. 2026 · NCT01042379

Atezolizumab + Sacituzumab Govitecan to Prevent Recurrence in TNBC (ASPRIA)

  • University of Pennsylvania-Abramson Cancer Center, Philadelphia
Prebieha náborFáza 2
Vek 18 a viac · Všetky pohlavia · Aktualizované 4. 5. 2026 · NCT04434040

ctDNA Positive Patients Diagnosed With cT1bN0 and cT1cN0 TNBC

  • UPMC Hillman Cancer, Pittsburgh
Prebieha náborObservačná štúdia
Vek 18 a viac · Ženy · Aktualizované 1. 5. 2026 · NCT07332975

Sacituzumab Govitecan +/- Pembrolizumab in Metastatic TNBC

  • University of Pennsylvania-Abramson Cancer Center, Philadelphia
Prebieha náborFáza 2
Vek 18 a viac · Všetky pohlavia · Aktualizované 29. 4. 2026 · NCT04468061

Investigating the Effectiveness of Stereotactic Body Radiotherapy (SBRT) in Addition to Standard of Care Treatment for Cancer That Has Spread Beyond the Original Site of Disease

  • Lehigh Valley Health Network, Allentown
Prebieha náborFáza 2
Vek 18 a viac · Všetky pohlavia · Aktualizované 27. 2. 2026 · NCT03808337

Pre-operative SABR With and Without Caloric Restriction for Early Stage Breast Cancer

  • Thomas Jefferson University Hospital, Philadelphia
Prebieha nábor
Vek 40 a viac · Všetky pohlavia · Aktualizované 23. 1. 2026 · NCT04959474

Phase 1/2 Study of Intratumoral Injection of STX-001 in Advanced Solid Tumors as Monotherapy or in Combination With Pembrolizumab

  • University of Pittsburgh Medical Center, Pittsburgh
Prebieha náborFáza 1/2
Vek 18 a viac · Všetky pohlavia · Aktualizované 29. 10. 2025 · NCT06249048

Role of the Immune Environment in Response to Therapy in Breast Cancer

  • Abramson Cancer Center, Philadelphia
Prebieha náborObservačná štúdia
Vek 18 a viac · Ženy · Aktualizované 8. 7. 2025 · NCT05396612

CtDNA Based MRD Testing for NAC Monitoring in TNBC

  • Cancer Care Associates of York, York
Prebieha náborObservačná štúdia
Vek 18 a viac · Ženy · Aktualizované 7. 1. 2025 · NCT06230185

Z ClinicalTrials.gov, dáta načítané 6. 10. 2026. Každá štúdia má vlastné kritériá oprávnenosti; tím štúdie rozhoduje o účasti.